$GOVX News

GeoVax Labs, Inc. (GOVX) Discusses Building a Resilient Infectious Disease Preparedness Strategy Focused on Ebola, Marburg, Hantavirus, and Mpox Transcript

GeoVax Stock Higher As Company Highlights MVA Platform For Ebola Threats

GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms; Company Highlights Potential Role of MVA-Based Vaccine Technologies in Addressing Emerging Hemorrhagic Fever Threats, Including Ebola and Marburg Viruses

Why Is GeoVax Labs Stock Falling Tuesday?

GeoVax Is The Holder Of Patent 11,701,418 Titled "Replication-deficient Modified Vaccinia Ankara (MVA) Expressing Ebola Virus Glycoprotein And Matrix Protein"

Geovax Labs Q1 EPS $(2.62) Beats $(4.42) Estimate

GeoVax Reports 2025 Year-End Financial Results and Provides Business Update

How The GeoVax Labs (GOVX) Story Is Shifting After The Rating Downgrade And Valuation Reset

GeoVax Positions GEO-MVA to Address Supply Constraints in Global Mpox and Smallpox Vaccine Market

GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026

GeoVax Announces a Warrant Inducement Transaction

Why The GeoVax Labs (GOVX) Story Is Shifting As Valuation Holds And Risks Rise

GeoVax Provides Update on GEO-MVA Program

GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients

How The Story On GeoVax Labs (GOVX) Is Shifting Toward Execution Risk And Funding Constraints

GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox Vaccine

GeoVax Announces Oncology Advisory Board to Advance Gedeptin(R) Development Across Solid Tumors

D. Boral Capital Downgrades Geovax Labs to Hold

GeoVax Secures Exclusive License for Gedeptin(R) + Immune Checkpoint Inhibitor Combination Technology

GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far From Over